ProVise Management Group’s Novavax NVAX Stock Holding History

ProVise Management Group’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-500	Closed	-$11K	–	323
2017 Q3	$11K	Hold	500	–	–	﹤0.01%	315
2017 Q2	$12K	Hold	500	–	–	﹤0.01%	325
2017 Q1	$13K	Buy	+500	New	+$13.8K	﹤0.01%	320
2016 Q4	–	Sell	-500	Closed	-$21K	–	340
2016 Q3	$21K	Hold	500	–	–	﹤0.01%	322
2016 Q2	$73K	Hold	500	–	–	0.01%	295
2016 Q1	$52K	Hold	500	–	–	0.01%	286
2015 Q4	$84K	Hold	500	–	–	0.02%	284
2015 Q3	$71K	Hold	500	–	–	0.02%	273
2015 Q2	$111K	Hold	500	–	–	0.02%	287
2015 Q1	$83K	Hold	500	–	–	0.02%	304
2014 Q4	$59K	Buy	+500	New	+$52.3K	0.01%	292

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProVise Management Group's NVAX Position: Q4 2017 in Review

ProVise Management Group sold out of Novavax (NVAX) in Q4 2017, closing a stake of 500 shares — an estimated $11K sold.

ProVise Management Group first reported a position in NVAX in Q4 2014 and held it in 11 quarters. The position peaked at $111K in Q2 2015. 134 funds tracked by Wall St. Rank hold NVAX as of Q4 2017.

ProVise Management Group reported no remaining Novavax position as of Q4 2017 after selling out during the quarter.
ProVise Management Group sold 500 Novavax shares in Q4 2017, an estimated $11K.
ProVise Management Group first reported a position in Novavax in Q4 2014 and held it in 11 quarters.
ProVise Management Group's Novavax position peaked at $111K in Q2 2015.
134 funds tracked by Wall St. Rank held Novavax as of Q4 2017.

Based on ProVise Management Group's 13F filing for Q4 2017, filed 7 Feb 2018.